Form S-8 Blueprint Medicines Corp
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Blueprint Medicines (BPMC) PT Raised to $98 at Wedbush
February 22, 2018 3:28 PM ESTWedbush raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $98.00 (from $96.00) while maintaining a Outperform rating.
Analyst David Nierengarten commented, "In addition to working toward enrollment of the registration-directed PDGFR-driven GIST trial set to complete mid-year, BPMC has moved... More
